COTELLIC® (cobimetinib) 20 mg tablets | ZELBORAF® (vemurafenib) 240 mg tablets

You are invited to attend a Genentech nurse clinical program:

A Case-Based Approach to Targeted Therapy With COTELLIC® (cobimetinib) and ZELBORAF® (vemurafenib) for *BRAF* V600E/K Mutation-Positive Unresectable or Metastatic Melanoma

This clinical presentation is designed for oncology nurses who may help treat patients taking COTELLIC + ZELBORAF and will review key clinical data and safety profile information.

This is a promotional program sponsored by Genentech. It is not intended to solicit questions or discussions related to product uses that are not approved by the FDA. No CME credits will be provided. Certain restrictions may apply.*

INDICATIONS AND USAGE

COTELLIC (cobimetinib) is indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with ZELBORAF (vemurafenib).

PRESENTED BY:	**Grace Cherry, MSN** Nurse Practitioner UCLA Oncology Los Angeles , CA
LOCATION:	**Fleming's Prime Steakhouse** 180 El Camino Real Palo Alto, CA 94304 (650) 329-8457
DATE/TIME:	**Thursday, August 10, 2017** 6:00 PM Pacific Time Arrival 6:30 PM Pacific Time Presentation
TO RSVP FOR THIS PROGRAM:	**RSVP by Saturday, August 05, 2017** Please log onto http://www.medforcereg.net/SGEN8742 If you have any questions, please contact Jason Smith at 845-522-1933

Please see reverse, Full COTELLIC Prescribing Information, and Full ZELBORAF Prescribing Information for Important Safety Information.

Genentech
A Member of the Roche Group

* **Minnesota, Vermont, the Department of Defense, and the Department of Veterans Affairs** have restrictions on receiving in-kind benefits (eg, meals, valet parking) at company-sponsored events. You are accountable for understanding such restrictions and complying with them. If you are licensed in or affiliated with any of these states or federal agencies, Genentech policies may restrict you from consuming any portion of the Genentech-sponsored meal at this program or from receiving any other in-kind benefit from Genentech (eg, valet parking) in connection with the program. When you RSVP please indicate whether you will accept or opt out of Genentech's in-kind benefits (eg, meals, valet parking) at the program. If you choose to opt out, you may either pay for the meal and parking on your own, or not consume anything at the program. For all program attendees who receive Genentech's in-kind benefits at this program, Genentech will report the attendee's name and the value received as required by federal and state disclosure laws (for more information on the federal law please visit http://sunshine.gene.com). The meal cost may vary by event location and be up to $125 per person (exceptions may apply).

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Review the Full Prescribing Information for ZELBORAF for information on the serious risks of ZELBORAF.

The following can occur in patients treated with COTELLIC:

New primary malignancies, including cutaneous and non-cutaneous malignancies; hemorrhage, including major hemorrhages; cardiomyopathy, defined as symptomatic and asymptomatic decline in left ventricular ejection fraction; severe dermatologic reactions, including rash and other skin reactions; serous retinopathy and retinal vein occlusion; hepatotoxicity; rhabdomyolysis; severe photosensitivity; embryo-fetal toxicity.

The following can occur in patients treated with ZELBORAF:

New primary malignancies including cutaneous squamous cell carcinoma, non-cutaneous squamous cell carcinoma, new primary melanoma, and other malignancies; tumor promotion in BRAF wild-type melanomas; serious hypersensitivity reactions including anaphylaxis; severe dermatologic reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis; QT prolongation; hepatotoxicity including liver injury leading to functional hepatic impairment (including coagulopathy or other organ dysfunction); increases in transaminases and bilirubin when concurrently administered with ipilimumab; photosensitivity; ophthalmologic reactions, including uveitis, blurry vision, and photophobia; embryo-fetal toxicity; radiation sensitization and radiation recall, including fatal cases in patients with visceral involvement; renal failure, including acute interstitial nephritis and acute tubular necrosis.

DRUG INTERACTIONS

Avoid concomitant administration of COTELLIC with strong or moderate CYP3A inducers or inhibitors.

Avoid concurrent use of ZELBORAF with strong CYP3A4 inhibitors, strong CYP3A4 inducers, and CYP1A2 and P-glycoprotein substrates with narrow therapeutic windows.

USE IN SPECIFIC POPULATIONS: Lactation

Advise women not to breastfeed during treatment with COTELLIC and ZELBORAF and for 2 weeks after the final dose of COTELLIC or ZELBORAF (whichever is taken later).

Most Common Adverse Reactions

The most common (≥20%) adverse reactions with COTELLIC were diarrhea (60%), photosensitivity reaction (46%), nausea (41%), pyrexia (28%) and vomiting (24%). The most common (≥5%) Grade 3-4 laboratory abnormalities were increased GGT (21%), increased CPK (14%), hypophosphatemia (12%), increased ALT (11%), lymphopenia (10%), increased AST (8%), increased alkaline phosphatase (7%), and hyponatremia (6%).

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see both accompanying Full COTELLIC Prescribing Information and Full ZELBORAF Prescribing Information for additional Important Safety Information.

COTELLIC® (cobimetinib) 20 mg tablets | ZELBORAF® (vemurafenib) 240 mg tablets